title: [Recent advances in the treatment of adrenocortical carcinomas].
abstract: Adrenocortical carcinomas are rare and aggressive malignant tumors, with an incidence of 1 to 2 cases per million inhabitants. Their diagnosis is made in three clinical situations: during the work up of a syndrome of hormonal hypersecretion, during the work up of locoregional symptoms, or incidentally during an unrelated radiological procedure. Surgery is usually indicated except in situations of advanced metastatic disease. Adjuvant chemotherapy with mitotane is associated with a significant increase in disease-free survival when the drug is administered at adequate therapeutic dosage. Novel anti-mitotic therapies have recently been described for treating recurrent adrenocortical carcinoma under mitotane treatment, but their overall efficacy remains unsatisfactory.
authors.affiliation: Service d'endocrinologie et diabétologie, Clinique de médecine, Hôpital cantonal, 1700 Fribourg.
authors.forename: J
authors.initials: J
authors.lastname: Ducry
authors.forename: D
authors.initials: D
authors.lastname: Berthold
authors.forename: F
authors.initials: F
authors.lastname: Pralong
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D018268:Adrenocortical Carcinoma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D050256:Antimitotic Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000379:methods; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015994:Incidence; D009364:Neoplasm Recurrence, Local
chemical_list: D050256:Antimitotic Agents; D000970:Antineoplastic Agents